Please login to the form below

Not currently logged in

Lundbeck's Steve Turley re-elected as EMG chair

And Actelion's Robin Bhattacherjee retains vice-chair position

Steve Turley, LundbeckThe European Medicines Group (EMG) has made several senior appointments, re-electing both Lundbeck's Steve Turley as chair and Actelion's Robin Bhattacherjee as vice-chair, and electing Servier's Mike Sumpter as treasurer.

The announcements were made at the annual general meeting of the EGM, which was formed in 2001 to represent UK affiliates of pharma companies headquartered in continental Europe.

Turley (pictured) was originally appointed chair of the Group last year after the departure of Matthew Speers, former managing director of UCB.

Turley has been managing director of Lundbeck's UK operations since 2009 following spells as general manager UK and Ireland at Actelion and business unit director at Roche.

Bhattacherjee took over as vice-chair of the EMG last year, replacing Turley, who he also took over from at Actelion with his 2009 appointment as general manager of the company's UK operations – a position he still holds.

Previously, Bhattacherjee worked at CV Therapeutic Europe as executive director and at Sanofi-Synthelabo as head of cardiovascular marketing. Prior to this, he spent 16 years at Bayer.

Meanwhile, Mike Sumpter has been CEO of Servier's UK business since 2008, a role that was preceded by a spell as CEO of the company's business in Canada.

16th May 2013

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...